286 related articles for article (PubMed ID: 27003928)
1. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis.
Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Hunt PM; Rudel R; Sathyanarayana S; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
Andrology; 2016 Jul; 4(4):565-72. PubMed ID: 27003928
[TBL] [Abstract][Full Text] [Related]
2. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.
Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
J Clin Endocrinol Metab; 2015 Apr; 100(4):1245-55. PubMed ID: 25742516
[TBL] [Abstract][Full Text] [Related]
3. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1256-66. PubMed ID: 25742515
[TBL] [Abstract][Full Text] [Related]
4. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis.
Attina TM; Hauser R; Sathyanarayana S; Hunt PA; Bourguignon JP; Myers JP; DiGangi J; Zoeller RT; Trasande L
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):996-1003. PubMed ID: 27765541
[TBL] [Abstract][Full Text] [Related]
5. Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union.
Hauser R; Skakkebaek NE; Hass U; Toppari J; Juul A; Andersson AM; Kortenkamp A; Heindel JJ; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1267-77. PubMed ID: 25742517
[TBL] [Abstract][Full Text] [Related]
6. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
Legler J; Fletcher T; Govarts E; Porta M; Blumberg B; Heindel JJ; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1278-88. PubMed ID: 25742518
[TBL] [Abstract][Full Text] [Related]
7. Female Reproductive Disorders, Diseases, and Costs of Exposure to Endocrine Disrupting Chemicals in the European Union.
Hunt PA; Sathyanarayana S; Fowler PA; Trasande L
J Clin Endocrinol Metab; 2016 Apr; 101(4):1562-70. PubMed ID: 27003299
[TBL] [Abstract][Full Text] [Related]
8. Human cost burden of exposure to endocrine disrupting chemicals. A critical review.
Bond GG; Dietrich DR
Arch Toxicol; 2017 Aug; 91(8):2745-2762. PubMed ID: 28528477
[TBL] [Abstract][Full Text] [Related]
9. Disease burden attributable to endocrine-disrupting chemicals exposure in China: A case study of phthalates.
Cao Y; Li L; Shen K; Liu J
Sci Total Environ; 2019 Apr; 662():615-621. PubMed ID: 30699382
[TBL] [Abstract][Full Text] [Related]
10. Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation.
Grandjean P; Bellanger M
Environ Health; 2017 Dec; 16(1):123. PubMed ID: 29202828
[TBL] [Abstract][Full Text] [Related]
11. Letter to the Editor: Re: Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union.
Middelbeek RJ; Veuger SA
J Clin Endocrinol Metab; 2015 Jun; 100(6):L52-3. PubMed ID: 26047084
[No Abstract] [Full Text] [Related]
12. Comparison of methods for calculating the health costs of endocrine disrupters: a case study on triclosan.
Prichystalova R; Fini JB; Trasande L; Bellanger M; Demeneix B; Maxim L
Environ Health; 2017 Jun; 16(1):55. PubMed ID: 28599657
[TBL] [Abstract][Full Text] [Related]
13. Economic impacts of environmentally attributable childhood health outcomes in the European Union.
Bartlett ES; Trasande L
Eur J Public Health; 2014 Feb; 24(1):21-6. PubMed ID: 23748596
[TBL] [Abstract][Full Text] [Related]
14. The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis.
Bonde JP; Flachs EM; Rimborg S; Glazer CH; Giwercman A; Ramlau-Hansen CH; Hougaard KS; Høyer BB; Hærvig KK; Petersen SB; Rylander L; Specht IO; Toft G; Bräuner EV
Hum Reprod Update; 2016 Dec; 23(1):104-125. PubMed ID: 27655588
[TBL] [Abstract][Full Text] [Related]
15. Exposure to Endocrine Disrupting Chemicals in Canada: Population-Based Estimates of Disease Burden and Economic Costs.
Malits J; Naidu M; Trasande L
Toxics; 2022 Mar; 10(3):. PubMed ID: 35324771
[TBL] [Abstract][Full Text] [Related]
16. Racial/ethnic disparities in disease burden and costs related to exposure to endocrine-disrupting chemicals in the United States: an exploratory analysis.
Attina TM; Malits J; Naidu M; Trasande L
J Clin Epidemiol; 2019 Apr; 108():34-43. PubMed ID: 30529005
[TBL] [Abstract][Full Text] [Related]
17. Endocrine-disrupting chemicals: Mainstream recognition of health effects and implications for the practicing internist.
Trasande L; Sargis RM
J Intern Med; 2024 Feb; 295(2):259-274. PubMed ID: 38037246
[TBL] [Abstract][Full Text] [Related]
18. Endocrine-disrupting chemicals: economic, regulatory, and policy implications.
Kassotis CD; Vandenberg LN; Demeneix BA; Porta M; Slama R; Trasande L
Lancet Diabetes Endocrinol; 2020 Aug; 8(8):719-730. PubMed ID: 32707119
[TBL] [Abstract][Full Text] [Related]
19. Population attributable risks and costs of diabetogenic chemical exposures in the elderly.
Trasande L; Lampa E; Lind L; Lind PM
J Epidemiol Community Health; 2017 Feb; 71(2):111-114. PubMed ID: 27789757
[TBL] [Abstract][Full Text] [Related]
20. European Union's strategy on endocrine disrupting chemicals and the current position of Slovenia.
Perharič L; Fatur T; Drofenik J
Arh Hig Rada Toksikol; 2016 Jun; 67(2):99-105. PubMed ID: 27331297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
